Advances in the design of combination therapies for the treatment of tuberculosis
Jonah Larkins‐Ford, Bree B. Aldridge
Expert Opinion on Drug Discovery · 2022-12
Abstract
INTRODUCTION: , and computational methodologies to interrogate combination drug effects. AREAS COVERED: This review discusses the advances in these methodologies and how they may be used in conjunction with new successful clinical trials of novel drug combinations to design optimized combination therapies for tuberculosis. Literature searches for approaches and experimental models used to evaluate drug combination effects were undertaken. EXPERT OPINION: We are entering an era richer in combination drug effect and pharmacokinetic/pharmacodynamic data, genetic tools, and outcome measurement types. Application of computational modeling approaches that integrate these data and produce predictive models of clinical outcomes may enable the field to generate novel, effective multidrug therapies using existing and new drug combination backbones.
MeSH terms
- Tuberculosis
- Drug
- Medicine
- Mycobacterium tuberculosis
- Drug development
- Expert opinion
- Intensive care medicine
- Clinical trial
- Drug resistance
- Computational biology
- Pharmacology